GEN-MKT-18-7897-A
Apr 28, 2017 | Blogs, Environmental / Industrial, Food / Beverage | 0 comments
There has been a string of news articles concerning polyfluorinated alkyl substances (PFAS) in drinking water these days, and I must say, they have my attention. Here is the thing, when you think of drinking water in the United States, for example, crystal clear lakes, rivers, and groundwater along with effective water treatment come to mind. On the flip side, as safe, some supplies may be there are communities such as that of Flint, Michigan, which have been dealing with lead filled pipes for far too long. Contamination was so bad there that residents were provided bottled water for drinking purposes as the state decided who was responsible for replacing the affected water lines.
However, it is not just Flint, Michigan that suffers from poor water quality. Take articles like, “Whidbey Island Drinking Water Polluted with Firefighting Chemicals,” which describes how not nice substances like PFAS, whose physicochemical properties make them important for use in a variety of industrial and consumer products including firefighting foam, have been found in soil and ground water. A problem, since even years later the contaminant managed to find its way into private wells thereby making people sick. Useful for industries, not so much for humans since PFAS have been implicated in the incidence of cancer, obesity, endocrine system disruption, and other adverse health effects.
Although the EPA does not regulate private wells, lab tests in Whidbey turned up levels 35 times more than the allowable standards. In a separate report from a Harvard study it is estimated as much as six million Americans might be affected by PFA contaminated water even though in 2015, The Environmental Protection Agency (EPA) developed a global stewardship program to phase out PFA from emissions and products. As a Food, Environment, and Forensic Scientist and a human being, I wonder along with my SCIEX partners and clients, what more can we do to test for such harmful matter as PFAS at low levels so we can help keep the public safe.
For you fellow scientists who wish to get into testing this PFA business, download the tech note to read about two methods for the quantitation of per- and polyfluorinated alkyl substances (PFAS) in water samples. While the MS/MS detection method using the SCIEX Triple Quad™ 5500 is similar between the two approaches, sample preparation and injection volume differ significantly.
I invite you to discover the advantages of each method including compatibility to EPA Method 533 and the ever important, straightforward sample preparation. With the growing need for PFAS analysis of environmental samples, these versatile methods will be most useful for labs aiming to evaluate growing lists of PFAS. Read the Tech Note >
Learn More About Drinking Water Testing >
In Case You Missed It:
*This content does not constitute legal advice. You should consult counsel to assure your procedures comply with applicable law and that it meets your needs.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
Posted by
You must be logged in to post a comment.
Share this post with your network